NCT02742532View on ClinicalTrials.gov

Oxytocin Suppresses Substance Use Disorders Associated With Chronic Stress

PHASE2CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

April 20, 2017

Primary Completion Date

July 1, 2019

Study Completion Date

July 1, 2019

Conditions
Alcohol Use DisorderStress Disorders, Post-TraumaticAnxiety DisordersSubstance Use Disorders
Interventions
DRUG

Oxytocin

Intranasal oxytocin 40 IU

DRUG

Placebo

Intranasal saline solution

Trial Locations (1)

92106

Naval Medical Center San Diego, San Diego

All Listed Sponsors
collaborator

United States Naval Medical Center, San Diego

FED

collaborator

United States Department of Defense

FED

collaborator

Congressionally Directed Medical Research Programs

FED

collaborator

Eisenhower Army Medical Center

FED

lead

Jennifer Mitchell

OTHER

NCT02742532 - Oxytocin Suppresses Substance Use Disorders Associated With Chronic Stress | Biotech Hunter | Biotech Hunter